Esketamine for treatment‐resistant depression: A review of clinical evidence (Review)

ABSTRACT: Treatment-resistant depression (TRD) is a challenge for psychiatrists, even after more than seven decades since the first antidepressants were used in clinical practice. Non-monoaminergic-based drugs with antidepressant properties have been developed, but to date, only esketamine and brexanolone have been approved for TRD and postpartum depression, respectively. A narrative review on the efficacy and safety of esketamine in the main categories of depressive disorders has been conducted through four electronic databases (Pubmed, Cochrane, EMBASE and Clarivate/Web of Science) The primary objective of the present review was to find evidence that may support the usefulness of esketamine for patients diagnosed with TRD as well as data about its potential adverse effects in the short and long te

SUBMITTER: Vasiliu O 

PROVIDER: S-EPMC9922941 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature